Back to search

United Kingdom· GB-APID-24796311000001105

Sylvant 400mg powder for concentrate for solution for infusion vials

A siltuximab product containing siltuximab, registered in United Kingdom by Recordati UK Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC L04AC11

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedSylvant 400mg powder for concentrate …ATCL04AC11REGISTER NO.GB-APID-2479631100000…PACKS LISTED4CHECKEDSeptember 13, 2026

Where it is registered

Siltuximab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC11 (siltuximab), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 9 of them publish a price we can compare per daily dose

Siltuximab · ATC L04AC11

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Siltuximab
Manufacturer
Recordati UK Ltd
Country
United Kingdom (GB)
ATC code
L04AC11
ATC class
Siltuximab
Defined daily dose
37 mg, P
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 4

  • gtin
    5012674902608
  • gtin
    05012674902608
  • gtin
    5060146292436
  • gtin
    5060146293051

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

151 interactions on record for siltuximab.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Siltuximab · interactions on record

151 records

  • 28 severe
  • 116 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/684ca9c8-5d84-4156-beb8-5940a5264a2b
GET /v1/drugs/684ca9c8-5d84-4156-beb8-5940a5264a2b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "24796311000001105",
  "desc": "Sylvant 400mg powder for concentrate for solution for infusion vials (Recordati UK Ltd)",
  "form": "Powder for solution for infusion",
  "vpid": "25091211000001101",
  "source": "dmd",
  "vtm_id": "777530000",
  "strength": "400 mg",
  "substance": "Siltuximab",
  "ingredient": "Siltuximab",
  "supplier_code": "13210911000001103"
}

See everything about siltuximab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.